IFN-γ Inhibitors
Common IFN-γ Inhibitors include, but are not limited to TGF-β RI Kinase Inhibitor VIII CAS 356559-20-1, 4-Hydroxy-2-mercapto-6-methylpyrimidine CAS 56-04-2, Sunitinib, Free Base CAS 557795-19-4, Cepharanthine CAS 481-49-2 and Ruxolitinib CAS 941678-49-5.
IFN-γ inhibitors belong to a chemical class of compounds designed to selectively interfere with the activity of interferon-gamma (IFN-γ), a cytokine involved in immune responses and inflammatory processes. IFN-γ plays a significant role in modulating the immune system by promoting the activation of immune cells and the release of other immune mediators. These inhibitors are developed to disrupt the signaling pathways that are triggered by the binding of IFN-γ to its receptors on target cells. By doing so, they aim to prevent the downstream effects and cellular responses that are initiated by IFN-γ stimulation.
The inhibitors are designed to interact with components of the IFN-γ signaling pathway, such as receptors, kinases, or downstream transcription factors, in order to block or dampen the cellular response to IFN-γ. By modulating the effects of IFN-γ, these compounds could impact immune responses and inflammation. The chemical structure and specific mechanism of action of each inhibitor may vary, but the overarching goal is to hinder the signaling cascade triggered by IFN-γ, thereby affecting immune cell activation and other IFN-γ-mediated processes in the body.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
TGF-β RI Kinase Inhibitor VIII | 356559-20-1 | sc-203295 | 2 mg | $100.00 | 2 | |
TGF-β RI Kinase Inhibitor VIII inhibits IFN-γ signaling by targeting TGF-β type I receptor, leading to downregulation of downstream pathways. | ||||||
4-Hydroxy-2-mercapto-6-methylpyrimidine | 56-04-2 | sc-238861 | 100 g | $113.00 | ||
4-Hydroxy-2-mercapto-6-methylpyrimidine suppresses IFN-γ production by inhibiting thyroid hormone synthesis, indirectly affecting immune response. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits tyrosine kinases, including those involved in IFN-γ signaling, thus interfering with immune activation. | ||||||
Cepharanthine | 481-49-2 | sc-391213 sc-391213A | 100 mg 500 mg | $45.00 $150.00 | 2 | |
Cepharanthine inhibits IFN-γ-induced JAK/STAT signaling, potentially modulating the immune response. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Fludarabine suppresses lymphocyte activation, including IFN-γ production, by interfering with DNA synthesis. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK inhibitor, attenuates IFN-γ signaling by targeting JAK kinases, modulating inflammatory pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, attenuating IFN-γ-induced immune responses by downregulating downstream pathways. | ||||||
PF-956980 | 1262832-74-5 | sc-478501 | 10 mg | $430.00 | ||
PF-956980 is a JAK3-selective inhibitor, disrupting IFN-γ signaling by blocking JAK3-mediated immune activation. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin modulates IFN-γ signaling by interfering with multiple pathways, potentially affecting immune responses. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG-490 inhibits JAK2 and EGFR, attenuating IFN-γ signaling and potentially regulating immune and inflammatory processes. | ||||||